Investment

SABADELL ASABYS Y ALTA LIFE SCIENCES APUESTAN POR EL GRAFENO EN EL ÁMBITO DE LAS TERAPIAS ELECTRONICAS NEURONALES Y COLIDERAN LA INVERSIÓN EN INBRAIN NEUROELECTRONICS

Laia Romero Leave a comment

Barcelona, 17 de junio de 2020  INBRAIN desarrolla dispositivos de grafeno inteligentes para la modulación electrónica neuronal contra trastornos cerebrales como el Parkinson y la Epilepsia entre otros Asabys Y Alta han liderado la inversión en INBRAIN para desarrollar una tecnología basada en Grafeno para la modulación electrónica neuronal que permite, tras la implantación intracerebral de un innovador electrodo, decodificar señales neuronales con alta fidelidad y producir una respuesta terapéutica…

Sanifit Enhances Leadership Team with New Executive Appointments

Laia Romero Leave a comment

Newly appointed VP of Business Development and SVP of Clinical Development each bring to Sanifit over 20 years of industry experience Palma, Spain and San Diego, USA, 01 June 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, is delighted to announce two new appointments to its Executive leadership team, with immediate effect. Hans Christian Keller joins the Company as Vice President of Business Development, and…

Accure Therapeutics launches with €7.6M Series A round

Laia Romero Leave a comment

Alta Life Sciences and the Centre for Technological and Industrial Development (CDTI) invest in new company that will develop portfolio of new medicines to address CNS diseases Barcelona, Spain, May 26, 2020 – Accure Therapeutics, a new pharma R&D player in the Central Nervous System (CNS) field, announces today its launch with a Series A round of funding totalling €7.6 million ($8.1M). The funding round was led by Alta Life…

Sanifit announces that the Phase 2b CaLIPSO trial of SNF472 met its primary endpoint in slowing the progression of cardiovascular calcification in patients on hemodialysis.

Laia Romero Leave a comment

Top line data to be presented at 2019 Scientific Sessions of American Heart Association Webcast to be held on Monday 18 November at 11.00 ET Palma, Spain and San Diego, USA, 30 October 2019 – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced that the international Phase 2b CaLIPSO study of SNF472 in patients with end stage kidney disease (ESKD) on hemodialysis has…

Sanifit named as one of 2019’s “Fierce 15” biotechnology companies by FierceBiotech

Adela Farré Leave a comment

Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders that is part of Alta Life Sciences portfolio, has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. In June 2019 Sanifit announced the completion of a €72.2 million (USD 80.9 million) private fundraising to further accelerate the clinical development…

Alta Life Sciences participates in Sanifit’s 55,2M€ Series D round led by Caixa Capital Risc

Alta Life Sciences

Proceeds to enable progression of orphan designated lead candidate SNF472 into pivotal phase 3 trial for treatment of calciphylaxis Round led by Spanish investor Caixa Capital Risc Columbus Venture Partners joins Alta Life Sciences as new investors, in addition to international consortium of existing shareholders Palma, Spain and San Diego, USA, 26 June 2019 – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced the…

Mediktor closes a funding round of 3 million euros with the aim of entering the US market

Alta Life Sciences

The round led by Alta Life Sciences, will reinforce the most advanced and accurate symptom checker, the only clinically validated in the world Start-up investors such as European-focused Castel Capital, French-based Naos, as well as other “business angels”, have also joined the round Barcelona, 12th of September 2018. Mediktor announces the closure of a Series A funding round for an amount of 3 million euros. Alta Life Sciences Spain I…

Alta Life Sciences is leading a 4M € round to finance the clinical development of the Bionures’s neuroprotector BN201

Alta Life Sciences

Alta Life Sciences is leading a Series A round of 4 million euros to finance the clinical development of Bionure’s lead compound BN201, that has demonstrated its potential to promote neuroprotection and remyelination in the preclinical phase, offering a game-changing solution for neurodegenerative diseases. Bionure, Barcelona based biotech company that develops neuroprotectant agents to treat neurodegenerative diseases primarily focusing on rare ophthalmologic diseases as Acute Optic Neuritis (AON) and Neuromyelitis…

Peptomyc S.L. secures 4.2 million euros in Series A led by Alta Life Sciences

Alta Life Sciences

Peptomyc S.L., a Barcelona-based biotech company developing new peptide therapeutics for the treatment of cancer patients, announces the closure of a Series A financing of 4.2 million euros. The investment round was led by Alta Life Sciences Spain I FCR, and includes current investors HealthEquity and business angels, that had already participated in the seed round of 2016. RCD, a leading legal firm in the biotech sector, has advised on…